Literature DB >> 34323622

Advances in pharmacotherapy for diabetic foot osteomyelitis.

Raju Ahluwalia1, Jose Luiz Lázaro-Martínez2, Ines Reichert1, Nicola Maffulli3,4,5.   

Abstract

Introduction: The diagnosis of diabetic foot osteomyelitis (DFO) is usually clinical. Its severity is related to the location and depth of the lesion, and the presence of necrosis or gangrene. The aetiology of diabetic foot osteomyelitis (DFO) is usually polymicrobial, and DFO is often associated with chronic or recurring ulceration.Areas covered: We built on the  International Working Group on the Diabetic Foot (IWGDF) guidelines on the management of diabetic foot infection, providing an outline of the current and new concepts in pharmacotherapy in DFO. We assess future strategies in both medical, surgical and combination management of DFO.Expert opinion: Surgical removal of infected bone is considered as the standard treatment, but a medical approach of certain selected situations has now proven efficacy in selected patients. The combination of new modalities in local antibiotic delivery may provide better long-term solutions and more lasting remission and avoid the disadvantages of prolonged systemic antibiotics.

Entities:  

Keywords:  antibiotic treatment; diabetic foot osteomyelitis; foot infection

Year:  2021        PMID: 34323622     DOI: 10.1080/14656566.2021.1954159

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  2 in total

1.  Impairment characteristics of static balance and plantar load distribution of patients undergoing tibial cortex transverse distraction for diabetic foot ulcers.

Authors:  Zhi-Qiang Fan; De-Wu Liu
Journal:  J Orthop Surg Res       Date:  2022-03-18       Impact factor: 2.359

Review 2.  Antibiotic-loaded calcium sulfate in clinical treatment of chronic osteomyelitis: a systematic review and meta-analysis.

Authors:  Xiangwen Shi; Yipeng Wu; Haonan Ni; Mingjun Li; Chaoqun Zhang; Baochuang Qi; Mingjie Wei; Teng Wang; Yongqing Xu
Journal:  J Orthop Surg Res       Date:  2022-02-19       Impact factor: 2.359

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.